Finance

Lists
Why is TRDA down 2,71%?
Dive Deeper
TRDA:NASDAQ
Entrada Therapeutics Inc
5,03 $
-2,71%
(-0,14) 1D
13 նոյ, 14:10:20 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TRDA...
Open
5,17 $
High
5,25 $
Low
4,91 $
Mkt. cap
196,34 մլն
Avg. vol.
451,72 հզր
Volume
212,48 հզր
52-wk high
16,45 $
52-wk low
4,11 $
EPS
-3,84 $
Beta
-0,19
Shares outstanding
39,15 մլն
No. of employees
152
Open
5,17 $
High
5,25 $
Low
4,91 $
Mkt. cap
196,34 մլն
Avg. vol.
451,72 հզր
Volume
212,48 հզր
52-wk high
16,45 $
52-wk low
4,11 $
EPS
-3,84 $
Beta
-0,19
Shares outstanding
39,15 մլն
No. of employees
152
News stories
From web sources and news partners
About Entrada Therapeutics Inc
CEO-
Employees152
Founded2016
HeadquartersԲոստոն, Մասսաչուսեթս, Միացյալ Նահանգներ
SectorHealth Care
Industry-
Websiteentradatx.com
Analyst ratings
Based on 4 analysts giving stock ratings to TRDA in the past 3 months
Strong buy
Buy
3
Hold
1
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for TRDA in the last 3 months.
Highest
Current 5,03 $
25,00 $ (+397,02%)
Average
19,33 $ (+284,29%)
Lowest
10,00 $ (+98,81%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ram Selvaraju
H.C. Wainwright
Hold
Reiterated
-
-
11/12/2026
Boobalan Pachaiyappan
Roth MKM
Buy
Reiterated
10,00 $
+98,8%
11/06/2026
Jonathan Miller
Evercore ISI
Buy
Maintained
25,00 $
+397%
10/15/2026
Kostas Biliouris
Oppenheimer
Buy
Reiterated
23,00 $
+357,3%
09/03/2026
Myles Minter
William Blair
Buy
Maintained
-
-
08/05/2026
Debjit Chattopadhyay
Guggenheim
Buy
Maintained
17,00 $
+238%
06/05/2026
Joseph Thome
TD Cowen
Buy
Maintained
-
-
05/07/2026
Yanni Souroutzidis
Cantor Fitzgerald
Buy
Initiated
-
-
04/01/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
2026 թ. սեպ
Revenue
1,30 մլն
875,00 հզր
898,00 հզր
905,00 հզր
Cost of goods sold
32,26 մլն
33,05 մլն
35,37 մլն
32,37 մլն
Cost of revenue
32,26 մլն
33,05 մլն
35,37 մլն
32,37 մլն
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
9,35 մլն
10,12 մլն
10,49 մլն
10,22 մլն
Operating expense
9,35 մլն
10,12 մլն
10,49 մլն
10,22 մլն
Total operating expenses
41,61 մլն
43,18 մլն
45,86 մլն
42,59 մլն
Operating income
-40,31 մլն
-42,30 մլն
-44,96 մլն
-41,69 մլն
Other non operating income
-
-
-
-
EBT including unusual items
-39,07 մլն
-39,68 մլն
-42,73 մլն
-39,72 մլն
EBT excluding unusual items
-37,17 մլն
-39,68 մլն
-42,73 մլն
-39,72 մլն
Income tax expense
92,00 հզր
38,00 հզր
35,00 հզր
27,00 հզր
Effective tax rate
-0,24%
-0,10%
-0,08%
-0,07%
Other operating expenses
-
-
-
-
Net income
-39,16 մլն
-39,72 մլն
-42,76 մլն
-39,74 մլն
Net profit margin
-3 014,93%
-4 539,09%
-4 762,03%
-4 391,38%
Earnings per share
-0,94
-0,95
-1,01
-0,94
Interest and investment income
3,14 մլն
2,62 մլն
2,24 մլն
1,97 մլն
Interest expense
-
-
-
-
Net interest expenses
3,14 մլն
2,62 մլն
2,24 մլն
1,97 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
-39,42 մլն
-41,50 մլն
-44,12 մլն
-41,02 մլն
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google Apps